Treatment of Myasthenia Gravis.
Neurol Clin
; 36(2): 311-337, 2018 05.
Article
em En
| MEDLINE
| ID: mdl-29655452
With specialized care, patients with myasthenia gravis can have very good outcomes. The mainstays of treatment are acetylcholinesterase inhibitors, and immunosuppressive and immunomodulatory therapies. There is good evidence thymectomy is beneficial in thymomatous and nonthymomatous disease. Nearly all of the drugs used for MG are considered "off-label." The 2 exceptions are acetylcholinesterase inhibitors and complement inhibition with eculizumab, which was recently approved by the US Food and Drug Administration for myasthenia gravis. This article reviews the evidence base and provides a framework for the treatment of myasthenia gravis, highlighting recent additions to the literature.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Miastenia Gravis
Limite:
Humans
Idioma:
En
Revista:
Neurol Clin
Ano de publicação:
2018
Tipo de documento:
Article
País de afiliação:
Estados Unidos